Lesion-Targeted Fusion Polypeptides for Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapy treatments for cancer are often insufficient and toxic due to non-specific distribution of pharmaceutical agents, leading to adverse side effects and ineffective targeting of cancer cells.
Innovation Solution
Development of lesion-targeted fusion polypeptides that combine an immunomodulator, such as GM-CSF, with a von Willebrand Factor-derived aptamer sequence and a rigid linker, which binds to exposed collagen in tissue lesions, allowing for targeted delivery and reduced systemic toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic chemotherapy is administered to treat cancer, then the pharmaceutical agent can reach cancer cells throughout the body, but the agent distributes non-specifically to both cancer cells and normal cells causing severe toxicity
Solution Approach 1:
The patent uses an exposed collagen-binding domain as an intermediary that mediates between the immunomodulator and the target tissue. This binding domain specifically recognizes and binds to exposed collagen at the tumor site, acting as a mediator that directs the immunomodulator to the cancer cells while preventing systemic distribution to normal cells. The intermediary enables selective delivery, resolving the contradiction between reaching cancer cells and avoiding normal cell toxicity.
Solution Approach 2:
The patent applies local quality by creating a fusion protein with heterogeneous structure where one portion (exposed collagen-binding domain) provides specific localization capability while another portion (immunomodulator) provides therapeutic function. The binding domain confers local targeting quality to the otherwise systemically distributed immunomodulator, enabling the drug to concentrate at the tumor site while sparing normal tissues from toxic effects.
2Reliability
If high doses of immunomodulators are administered systemically to achieve sufficient immune activation, then the immune response can be strengthened, but the adverse side effects increase significantly
Solution Approach 1:
The exposed collagen-binding domain serves as a mediator that enables low-dose immunomodulator administration to achieve high local concentration at the tumor site. The intermediary binding domain concentrates the immunomodulator where it is needed, allowing sufficient immune activation without the need for high systemic doses that would cause adverse side effects.
Solution Approach 2:
The patent changes the distribution parameter of the immunomodulator from systemic to localized by fusing it with the exposed collagen-binding domain. This parameter change enables the immunomodulator to achieve high local concentration at the tumor site while maintaining low systemic concentration, thereby strengthening the immune response at the target site without increasing adverse side effects.
3Ease of operation
If non-targeted immunomodulators are administered to treat cancer, then the treatment can be simplified, but the specific activity and targeting efficiency are insufficient
Solution Approach 1:
The patent merges the exposed collagen-binding domain with the immunomodulator into a single fusion protein. This combination integrates the targeting function (binding to exposed collagen) with the therapeutic function (immune modulation) in one molecule. The merged structure maintains the simplicity of single-agent administration while achieving precise targeting, resolving the contradiction between ease of operation and targeting precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables efficient and selective targeting of immunomodulators to cancer and infectious lesions, minimizing side effects and requiring lower doses, while improving the specific activity of the fusion polypeptides compared to non-targeted administration.
Implementation Method 1
The XC-binding aptamer sequence targets (e.g., binds) the polypeptide to the exposed collagen in tissue lesions
Data Source
AI summary
Provided herein are new compositions and methods to target pharmaceutical agents to pathological areas by utilizing fusion polypeptides. These fusion polypeptides contain two or more domains: (i) aptamer sequences that bind to exposed collagenous (XC-) proteins present in pathological areas, including cancerous and viral lesions, (ii) immunomodulators, such as cytokines, and optionally (iii) at least one linker joining the two domains or at the terminus of the polypeptide. In some cases, the linker is a rigid linker, e.g., a rigid helical linker. Also provided herein are methods of treating cancer and/or infectious diseases using the new fusion polypeptides.